Activation of the Aryl Hydrocarbon Receptor Leads to Resistance to EGFR TKIs in Non–Small Cell Lung Cancer by Activating Src-mediated Bypass Signaling
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Purpose: The aryl hydrocarbon receptor (AhR) has been generally recognized as a ligand-activated transcriptional factor that responds to xenobiotic chemicals. Recent studies have suggested that the expression of AhR varies widely across different cancer types and cancer cell lines, but its significance in cancer treatment has yet to be clarified. Experimental Design: AhR expression in non–small cell lung cancer (NSCLC) was determined by Western blotting and IHC staining. In vitro and in vivo functional experiments were performed to determine the effect of AhR on sensitivity to targeted therapeutics. A panel of biochemical assays was used to elucidate the underlying mechanisms. Results: A high AhR protein level indicated an unfavorable prognosis for lung adenocarcinoma. Inhibition of AhR signaling sensitized EGFR tyrosine kinase inhibitors (TKIs) in NSCLC cells that express high level of endogenous AhR protein. Notably, activation of AhR by pharmacologic and molecular approaches rendered EGFR-mutant cells resistant to TKIs by restoring PI3K/Akt and MEK/Erk signaling through activation of Src. In addition, we found that AhR acts as a protein adaptor to mediate Jak2–Src interaction, which does not require the canonical transcriptional activity of AhR. Conclusions: Our results reveal a transcription-independent function of AhR and indicate that AhR may act as a protein adaptor that recruits kinases bypassing EGFR and drives resistance to TKIs. Accordingly, targeting Src would be a strategy to overcome resistance to EGFR TKIs in AhR-activated NSCLC. Clin Cancer Res; 24(5); 1227–39. ©2017 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383 · cited 1×
“Numerous studies have shown that Stat proteins are primarily phosphorylated by Janus kinase 2 (Jak2, not represented in the kinase array) [39-41].”
BackgroundCrizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381 · cited 1×
“The clinical application of epidermal growth factor receptor (EGFR) inhibitors, anaplastic lymphoma kinase (ALK) inhibitors and ROS1 kinase inhibitors markedly extended the progression-free survival (PFS) of genetically defined NSCLC patients [12-14].”
BackgroundTargeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445 · cited 1×
“interest of overcoming resistance driven by these mechanisms, increasing efforts have been focused on the development of more potent tyrosine kinase inhibitors (TKIs) and combinational strategies, which ultimately suppress the major cell-survival-related output of tyrosine kinases, such as PI3K/Akt and MEK/Erk signali…”
BackgroundUyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305 · cited 1×
“In addition, the indoleamine 2,3-dioxygenase (IDO) and tryptophan-2,3-dioxygenase (TDO) inhibitors that inhibit Kyn, an endogenous AhR ligand, potentiate chemotherapy and immunotherapy, and clinical trials evaluating their safety and efficacy in cancers are currently under way [43-45].”
BackgroundCrizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964 · cited 1×
“The clinical application of epidermal growth factor receptor (EGFR) inhibitors, anaplastic lymphoma kinase (ALK) inhibitors and ROS1 kinase inhibitors markedly extended the progression-free survival (PFS) of genetically defined NSCLC patients [12-14].”
BackgroundAn endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
Opitz, C. A., Litzenburger, U. M., Sahm, F., Ott, M., Tritschler, I., Trump, S., Schumacher, T., Jestaedt, L., Schrenk, D., Weller, M., et al. (2011) · Nature · doi:10.1038/nature10491 · Cited by 1,898
Control of Treg and TH17 cell differentiation by the aryl hydrocarbon receptor
Quintana, F. J., Basso, A. S., Iglesias, A. H., Korn, T., Farez, M. F., Bettelli, E., Caccamo, M., Oukka, M., & Weiner, H. L. (2008) · Nature · doi:10.1038/nature06880 · Cited by 1,865
The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins
Veldhoen, M., Hirota, K., Westendorf, A. M., Buer, J., Dumoutier, L., Renauld, J.-C., & Stockinger, B. (2008) · Nature · doi:10.1038/nature06881 · Cited by 1,634
Muller, A. J., DuHadaway, J. B., Donover, P. S., Sutanto-Ward, E., & Prendergast, G. C. (2005) · Nature Medicine · doi:10.1038/nm1196 · Cited by 1,064 · cited 1×
“In addition, the indoleamine 2,3-dioxygenase (IDO) and tryptophan-2,3-dioxygenase (TDO) inhibitors that inhibit Kyn, an endogenous AhR ligand, potentiate chemotherapy and immunotherapy, and clinical trials evaluating their safety and efficacy in cancers are currently under way [43-45].”
BackgroundJAK/STAT signaling in hematological malignancies
Vainchenker, W., & Constantinescu, S. N. (2013) · Oncogene · doi:10.1038/onc.2012.347 · Cited by 528
Cited by
The therapeutic potential of targeting tryptophan catabolism in cancer
Opitz, C. A., Somarribas Patterson, L. F., Mohapatra, S. R., Dewi, D. L., Sadik, A., Platten, M., & Trump, S. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0664-6 · Cited by 300
Gong, K., Guo, G., Panchani, N., Bender, M. E., Gerber, D. E., Minna, J. D., Fattah, F., Gao, B., Peyton, M., Kernstine, K., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0048-0 · Cited by 92
The AhR‐SRC axis as a therapeutic vulnerability in BRAFi‐resistant melanoma
Paris, A., Tardif, N., Baietti, F. M., Berra, C., Leclair, H. M., Leucci, E., Galibert, M., & Corre, S. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202215677 · Cited by 26
Metadata
- Authors
- Ye, M., Zhang, Y., Gao, H., Xu, Y., Jing, P., Wu, J., Zhang, X., Xiong, J., Dong, C., Yao, L., Zhang, J., & Zhang, J.
- Venue
- Clinical Cancer Research
- Published
- 2018-02-28
- Volume
- 24
- Issue
- 5
- Pages
- 1227-1239
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2773938961
- Cited by
- 80
- References
- 15
- FWCI
- 5.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Activation of the Aryl Hydrocarbon Receptor Leads to Resistance to EGFR TKIs in Non–Small Cell Lung Cancer by Activating Src-mediated Bypass Signaling. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-17-0396
- The paper
- Ye, M., Zhang, Y., Gao, H., Xu, Y., Jing, P., Wu, J., Zhang, X., Xiong, J., Dong, C., Yao, L., Zhang, J., & Zhang, J. (2018). Activation of the Aryl Hydrocarbon Receptor Leads to Resistance to EGFR TKIs in Non–Small Cell Lung Cancer by Activating Src-mediated Bypass Signaling. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-0396
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.